Galectin‐3 as a candidate upstream biomarker for quantifying risks of myocardial ageing

Galectin‐3 (Gal‐3) is implicated in the pathogenesis of heart failure and is also influenced by ageing. This study aims to determine the extent to which Gal‐3 levels estimate odds of myocardial dysfunction in ageing cohorts, ‘upstream’ prior to clinical disease.

[1]  C. Apovian,et al.  Galectin‐3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients , 2019, Journal of the American Heart Association.

[2]  Jian-Min Yuan,et al.  Dissecting Clinical and Metabolomics Associations of Left Atrial Phasic Function by Cardiac Magnetic Resonance Feature Tracking , 2018, Scientific Reports.

[3]  Sanjiv J. Shah,et al.  Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.

[4]  K. Brown,et al.  Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension , 2016, Heart and Vessels.

[5]  A. Lucia,et al.  Galectin-3, osteopontin and successful aging , 2016, Clinical chemistry and laboratory medicine.

[6]  M. Halushka,et al.  Galectin‐3 and Risk of Heart Failure and Death in Blacks and Whites , 2016, Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.

[7]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[8]  K. Sakamoto,et al.  Clinical significance of plasma galectin-3 in patients with coronary artery disease. , 2015, International journal of cardiology.

[9]  M. Su,et al.  Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices , 2015, Scientific Reports.

[10]  F. Neumann,et al.  High-sensitivity cardiac troponin for risk prediction in patients with and without coronary heart disease. , 2014, International journal of cardiology.

[11]  R. D. de Boer,et al.  Renal Handling of Galectin‐3 in the General Population, Chronic Heart Failure, and Hemodialysis , 2014, Journal of the American Heart Association.

[12]  E. Rimm,et al.  Fibrosis-Related Biomarkers and Incident Cardiovascular Disease in Older Adults: The Cardiovascular Health Study , 2014, Circulation. Arrhythmia and electrophysiology.

[13]  J. Gaziano,et al.  Plasma galectin 3 and heart failure risk in the Physicians' Health Study , 2014, European journal of heart failure.

[14]  J. D. de Lemos,et al.  Prevalence and significance of detectable troponins as measured by highly sensitive assays in the general population , 2013, Coronary artery disease.

[15]  Chia-Ying Liu,et al.  Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). , 2013, Journal of the American College of Cardiology.

[16]  T. Aw,et al.  Measurement of cardiac troponin I in serum with a new high-sensitivity assay in a large multi-ethnic Asian cohort and the impact of gender. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[17]  Bertram Pitt,et al.  Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis , 2013, Circulation. Heart failure.

[18]  D. Levy,et al.  Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. , 2012, Journal of the American College of Cardiology.

[19]  C. Liang,et al.  Relationship of Plasma Galectin-3 to Renal Function in Patients With Heart Failure: Effects of Clinical Status, Pathophysiology of Heart Failure, and Presence or Absence of Heart Failure , 2012, Journal of the American Heart Association.

[20]  P. Harst,et al.  The fibrosis marker galectin‐3 and outcome in the general population , 2012, Journal of internal medicine.

[21]  L. Trinquart,et al.  Underrepresentation of Elderly People in Randomised Controlled Trials. The Example of Trials of 4 Widely Prescribed Drugs , 2012, PloS one.

[22]  D. Rosene,et al.  Immunophenotypic Alterations in Resident Immune Cells and Myocardial Fibrosis in the Aging Rhesus Macaque (Macaca mulatta) Heart , 2012, Toxicologic pathology.

[23]  J. Cleland,et al.  Association of galectin‐3 and fibrosis markers with long‐term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE‐HF (Cardiac Resynchronization in Heart Failure) trial , 2012, European journal of heart failure.

[24]  P. McCullough,et al.  Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. , 2011, Reviews in cardiovascular medicine.

[25]  P. Muntendam,et al.  Galectin-3 in heart failure: high levels are associated with all-cause mortality. , 2011, International journal of cardiology.

[26]  R. D. du Bois,et al.  Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program , 2011, Expert review of respiratory medicine.

[27]  M. Donohue,et al.  Pirfenidone for diabetic nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[28]  P. Winyard,et al.  Modified Citrus Pectin Reduces Galectin-3 Expression and Disease Severity in Experimental Acute Kidney Injury , 2011, PloS one.

[29]  Antonio Cherubini,et al.  The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. , 2011, Archives of internal medicine.

[30]  K. Rhee,et al.  Matrilysin‐1 (MMP7) cleaves galectin‐3 and inhibits wound healing in intestinal epithelial cells , 2011, Inflammatory bowel diseases.

[31]  Hans L Hillege,et al.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.

[32]  M. Picard,et al.  Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure , 2010, European journal of heart failure.

[33]  D. Goldberg,et al.  Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. , 2010, American journal of public health.

[34]  H. Hillege,et al.  Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study , 2010, Clinical Research in Cardiology.

[35]  Edward G Lakatta,et al.  Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. , 2009, The Medical clinics of North America.

[36]  O. Carretero,et al.  N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. , 2009, American journal of physiology. Heart and circulatory physiology.

[37]  G. Rabinovich,et al.  Galectins: structure, function and therapeutic potential , 2008, Expert Reviews in Molecular Medicine.

[38]  Kenneth McDonald,et al.  Diastolic Heart Failure: Evidence of Increased Myocardial Collagen Turnover Linked to Diastolic Dysfunction , 2007, Circulation.

[39]  R. McKelvie,et al.  Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. , 2007, Journal of the American College of Cardiology.

[40]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[41]  B. Levine,et al.  Effect of Aging and Physical Activity on Left Ventricular Compliance , 2004, Circulation.

[42]  W. Gaasch,et al.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. , 2004, The New England journal of medicine.

[43]  Daniel Levy,et al.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. , 2003, Circulation.

[44]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[45]  Daniel Levy,et al.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. , 2003, Circulation.

[46]  Motoaki Sugawara,et al.  Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. , 2002, Cardiovascular research.

[47]  D O Stram,et al.  Singapore Chinese Health Study: Development, Validation, and Calibration of the Quantitative Food Frequency Questionnaire , 2001, Nutrition and cancer.

[48]  J. Gardin,et al.  Importance of heart failure with preserved systolic function in patients ≥65 years of age , 2001 .

[49]  J. Gardin,et al.  Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. , 2001, The American journal of cardiology.

[50]  J. Michel,et al.  Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. , 1999, Cardiovascular research.

[51]  L. Liotta,et al.  Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. , 1994, Biochemistry.

[52]  Jian-Min Yuan,et al.  Metabolomic profile of arterial stiffness in aged adults , 2018, Diabetes & vascular disease research.

[53]  J. Ochieng,et al.  Extracellular functions of galectin-3 , 2004, Glycoconjugate Journal.

[54]  E. Lakatta.  Changes in cardiovascular function with aging. , 1990, European heart journal.